Pascal and Francis Bibliographic Databases

Help

Search results

Your search

au.\*:("LINDMAN H")

Document Type [dt]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Publication Year[py]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Discipline (document) [di]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Author Country

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Results 1 to 15 of 15

  • Page / 1

Export

Selection :

  • and

CONSTANT CURVATURE RIEMANNIAN SCALING.LINDMAN H; CAELLI T.1978; J. MATH. PSYCHOL.; USA; DA. 1978; VOL. 17; NO 2; PP. 89-109; BIBL. 26 REF.Article

SUBJECTIVE LORENTZ TRANSFORMATIONS AND THE PERCEPTION OF MOTION.CAELLI T; HOFFMAN W; LINDMAN H et al.1978; J. OPT. SOC. AMER.; U.S.A.; DA. 1978; VOL. 68; NO 3; PP. 402-411; BIBL. 27 REF.Article

Use of TPS and CA 15-3 assays for monitoring chemotherapy in metastatic breast cancer patientsEINARSSON, R; LINDMAN, H; BERGH, J et al.Anticancer research. 2000, Vol 20, Num 6D, pp 5089-5093, issn 0250-7005Article

Suramin inhibits the growth of human breast cancer cell lines. Studies on parental lines and corresponding sublines with acquired doxorubicin resistance with and without expression of P-glycoproteinLINDMAN, H; TAUBE, A; BERGH, J. C. S et al.Anticancer research. 1994, Vol 14, Num 2A, pp 363-366, issn 0250-7005Article

Health care costs for treatment of disseminated breast cancerDAHLBERG, L; LUNDKVIST, J; LINDMAN, H et al.European journal of cancer (1990). 2009, Vol 45, Num 11, pp 1987-1991, issn 0959-8049, 5 p.Article

Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patientsSANDSTRÖM, M; LINDMAN, H; NYGREN, P et al.Cancer chemotherapy and pharmacology. 2006, Vol 58, Num 2, pp 143-156, issn 0344-5704, 14 p.Article

Cognitive TheoryRESTLE, F; SHIFFRIN, R. M; CASTELLAN, N. J et al.sd, 319 p.Book

Model describing the relationship between pharmacokinetics and hematologic toxicity of the epirubicin-docetaxel regimen in breast cancer patientsSANDSTRÖM, M; LINDMAN, H; NYGREN, P et al.Journal of clinical oncology. 2005, Vol 23, Num 3, pp 413-421, issn 0732-183X, 9 p.Article

Early response of breast cancer bone metastases to chemotherapy evaluated with MR imagingCIRAY, I; LINDMAN, H; ASTRÖM, K. G. O et al.Acta radiologica (1987). 2001, Vol 42, Num 2, pp 198-206, issn 0284-1851Article

Effect of granulocyte colony-stimulating factor (G-CSF)-supported chemotherapy on MR imaging of normal red bone marrow in breast cancer patients with focal bone metastasesCIRAY, I; LINDMAN, H; ASTRÖM, G. K. O et al.Acta radiologica (1987). 2003, Vol 44, Num 5, pp 472-484, issn 0284-1851, 13 p.Article

Can axillary dissection be avoided by improved molecular biological diagnosis?LINDAHL, T; ENGEL, G; AHLGREN, J et al.Acta oncologica (Stockholm). 2000, Vol 39, Num 3, pp 319-326, issn 0284-186XConference Paper

FEC mobilized stem cells for high-dose therapy in breast cancer patientsLINDMAN, H; WIKLUND, T; HOLTE, H et al.Acta oncologica (Stockholm). 1999, Vol 38, Num 2, pp 239-245, issn 0284-186XArticle

Time dependent effects of adjuvant tamoxifen therapy on cerebrovascular disease: results from a randomised trialROSELL, J; NORDENSKJÖLD, B; BENGTSSON, N.-O et al.British journal of cancer. 2011, Vol 104, Num 6, pp 899-902, issn 0007-0920, 4 p.Article

High-dose chemotherapy with autologous stem cell support in patients with responding stage IV breast cancerLJUNGMAN, P; BJÖRKSTRAND, B; VILLMAN, K et al.Bone marrow transplantation (Basingstoke). 1998, Vol 22, Num 5, pp 445-448, issn 0268-3369Article

Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapyWILKING, N; LIDBRINK, E; WIST, E et al.Annals of oncology. 2007, Vol 18, Num 4, pp 694-700, issn 0923-7534, 7 p.Article

  • Page / 1